New Patch Pump Options Highlighted at ADCES 2026

Simplified insulin delivery devices are drawing renewed clinical interest as an alternative to increasingly complex automated insulin delivery (AID) systems, offering patients injection-free mealtime and basal dosing without the programming burden of a full pump.

On a recent episode of Diabetes Dialogue, hosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, discussed new patch pump technology showcased at the 2026 conference of the Association of Diabetes Care & Education Specialists (ADCES). The discussion centered on emerging devices from Modular Medical and CeQur.

Watch the full episode, featuring tech, screening, and care updates from ADCES 2026, here.

Modular Medical's Pivot pump is a tubeless patch, worn for ≤3 days, holding ≤300 units of insulin. Each button press delivers a fixed 2-unit bolus, without carbohydrate counting or a bolus calculator. Unlike single fixed-rate devices such as V-Go, Pivot allows clinicians to program 2 distinct basal rates, adding flexibility while keeping the interface simple.1

CeQur's Simplicity patch, previously limited to 3-4-day wear and 2-unit dosing, has moved toward an extended 7-day wear time with capacity ≤240 units and a new 1-unit dosing option for finer titration. Because Simplicity delivers mealtime insulin only, it still requires a separate long-acting basal insulin, positioning it as a potential companion to once-weekly basal insulins and incretin therapies as those agents reach the market. Combining these once-weekly options with Simplicity could let patients consolidate several therapies into a single day of dosing each week.2

Modular Medical has indicated plans to pursue full automation for Pivot by partnering with a sensor and dosing algorithm, a step expected to require additional development, clinical study, and regulatory review over approximately 2 years. In the meantime, both devices reflect a countervailing trend in diabetes technology, prioritizing simplified, lower-burden insulin delivery for patients on multiple daily injections not seeking full automation.1

Editors’ Note: Isaacs reports disclosures with Dexcom, Abbott, Lilly, Novo Nordisk, Medtronic, Insulet, and others. Bellini reports disclosures with Abbott Diabetes Care, MannKind, Povention Bio, and others.

References

1. Modular Medical. Modular Medical Announces Launch of Pivot Insulin Delivery System Across Five Key U.S. Markets Beginning October 2026. BioSpace. August 3, 2026. Accessed August 11, 2026. https://www.biospace.com/press-releases/modular-medical-announces-launch-of-pivot-insulin-delivery-system-across-five-key-u-s-markets-beginning-october-2026

2. CeQur Simplicity. Extended 7-Day Wear and 1-Unit Dosing Clearances, and Two ADA Posters Signal a New Standard for Mealtime Insulin Management. June 4, 2026. Accessed August 11, 2026. https://myceqursimplicity.com/cequr-announces-exciting-advancements-2-recent-fda-clearances-and-new-clinical-evidence-to-be-presented-at-ada/